| Sequim Health & Rehabilitation | |
| 650 West Hemlock St, Sequim, Washington 98382 | |
| (360) 582-2400 | |
| Name | Sequim Health & Rehabilitation |
|---|---|
| Location | 650 West Hemlock St, Sequim, Washington |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 100 |
| Occupancy Rate | 87.2% |
| Medicare ID (CCN) | 505128 |
| Legal Business Name | Sequim Health, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1245743079 |
| Organization Name | SEQUIM HEALTH, LLC |
| Doing Business As | SEQUIM HEALTH & REHABILITATION |
| Address | 650 W Hemlock St, Sequim, WA 98382 |
| Phone Number | 360-582-2400 |
News Archive
New research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.
GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.
Current research does not support the use of smell tests for predicting Alzheimer's dementia, according to a comprehensive review by Robert Wood Johnson Foundation Clinical Scholars at the University of Michigan and the VA Center for Clinical Management Research.
› Verified 6 days ago
| NPI Number | 1285032573 |
| Organization Name | FMG WEST HEMLOCK STREET WASHINGTON LLC |
| Doing Business As | SEQUIM HEALTH & REHABILITATION CENTER |
| Address | 650 W Hemlock St, Sequim, WA 98382 |
| Phone Number | 360-582-2400 |
News Archive
New research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.
GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.
Current research does not support the use of smell tests for predicting Alzheimer's dementia, according to a comprehensive review by Robert Wood Johnson Foundation Clinical Scholars at the University of Michigan and the VA Center for Clinical Management Research.
› Verified 6 days ago
| NPI Number | 1780759977 |
| Organization Name | SEQUIM HEALTH, LLC |
| Doing Business As | SEQUIM HEALTH AND REHABILITATION |
| Address | 650 W Hemlock St, Sequim, WA 98382 |
| Phone Number | 360-582-2400 |
News Archive
New research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.
GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.
Current research does not support the use of smell tests for predicting Alzheimer's dementia, according to a comprehensive review by Robert Wood Johnson Foundation Clinical Scholars at the University of Michigan and the VA Center for Clinical Management Research.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
New research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.
GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.
Current research does not support the use of smell tests for predicting Alzheimer's dementia, according to a comprehensive review by Robert Wood Johnson Foundation Clinical Scholars at the University of Michigan and the VA Center for Clinical Management Research.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 3 |
| Total Amount of Fines in Dollars | $104468 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 3 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.54 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.11 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.26 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.73 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.43 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 14.35 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.56 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 89.34 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 16.03 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 59.9 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.5 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.01 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.75 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.31 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 84.17 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 79.75 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 66.67 | 82.93 |
News Archive
New research suggests these hidden genes hold the blueprints for designing new, even more effective cancer-targeting compounds.
GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.
Current research does not support the use of smell tests for predicting Alzheimer's dementia, according to a comprehensive review by Robert Wood Johnson Foundation Clinical Scholars at the University of Michigan and the VA Center for Clinical Management Research.
› Verified 6 days ago
Sequim Health & Rehabilitation Location: 650 West Hemlock St, Sequim, Washington 98382 Phone: (360) 582-2400 | |
Avamere Olympic Rehabilitation Of Sequim Location: 1000 5th Avenue South, Sequim, Washington 98382 Phone: (360) 582-3900 |